Glutamine is an abundant and highly versatile nutrient whose metabolism has implications for tumor cell biology, making it an appealing target for new clinical strategies to detect, monitor and treat cancer. Ralph DeBerardinis, M.D., Ph.D., Director of the Genetic and Metabolic Disease Program at the Children’s Research Institute at UT Southwestern (CRI); Ajla Wasti, M.D., a clinical fellow at CRI; and Chris Hensley, an M.D./Ph.D. student at CRI, have evaluated the metabolic functions of glutamine and its involvement in supporting tumor malignancy, in an effort to better understand how the information could be used in clinical oncology.
Read their research review published in The Journal of Clinical Investigation.
